Form 4: Tyra Biosciences CFO Alan Fuhrman Reports Stock Option Grant

Alan Fuhrman, CFO of Tyra Biosciences, reports the acquisition of stock options in the company.

Summary

• On August 14, 2024, Alan Fuhrman, the Chief Financial Officer of Tyra Biosciences, acquired 115,000 stock options with an exercise price of $21.57.
• These options vest monthly over a four-year period, commencing on August 14, 2024, contingent upon continuous service to the company.
• Following this transaction, Fuhrman directly owns 115,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own. The alignment of management's interests with shareholders is a mild positive.

Positives

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests and assess management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CFO's interests with the company's long-term success.

Key Dates